share_log

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K: Current report

Recursion Pharmaceuticals | 8-K:重大事件
美股SEC公告 ·  08/06 16:05

Moomoo AI 已提取核心訊息

Recursion Pharmaceuticals, Inc. reported on August 6, 2024, that it has successfully executed an option under its existing Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, originally signed on December 5, 2021. The option pertains to the first Neuroscience Phenomap that Recursion has generated. As a result of this exercise, Roche will pay Recursion an Acceptance Fee totaling $30 million. This financial event is part of the ongoing collaboration between the companies in the field of neuroscience.
Recursion Pharmaceuticals, Inc. reported on August 6, 2024, that it has successfully executed an option under its existing Collaboration and License Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd, originally signed on December 5, 2021. The option pertains to the first Neuroscience Phenomap that Recursion has generated. As a result of this exercise, Roche will pay Recursion an Acceptance Fee totaling $30 million. This financial event is part of the ongoing collaboration between the companies in the field of neuroscience.
Recursion Pharmaceuticals, Inc.於2024年8月6日報道,已成功根據其與Genentech, Inc.和F. Hoffmann-La Roche Ltd之間於2021年12月5日簽署的現有合作及許可協議中的一個條款執行了一項選擇權。此選擇權與Recursion生成的第一個神經科學Phenomap相關。因此,羅氏將向Recursion支付總計3000萬美元的認可費。這一財務事件是兩家公司在神經科學領域持續合作的一部分。
Recursion Pharmaceuticals, Inc.於2024年8月6日報道,已成功根據其與Genentech, Inc.和F. Hoffmann-La Roche Ltd之間於2021年12月5日簽署的現有合作及許可協議中的一個條款執行了一項選擇權。此選擇權與Recursion生成的第一個神經科學Phenomap相關。因此,羅氏將向Recursion支付總計3000萬美元的認可費。這一財務事件是兩家公司在神經科學領域持續合作的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息